United States: FDA Issues Draft Guidance On Use Of "Real-World Evidence" In Medical Device Decision-Making

Michael Gaba is a Partner and Jennifer Nowak is an Associate in Holland & Knight's Washington D.C. office

HIGHLIGHTS:

  • The U.S. Food and Drug Administration (FDA) issued draft guidance addressing how it may use data and evidence collected outside of the traditional clinical trial context to support medical device regulatory decision-making.
  • The draft guidance acknowledges that certain "real-world data" (RWD) and associated "real-world evidence" (RWE) could constitute valid scientific evidence that could be used in some FDA regulatory contexts.
  • While the guidance allows the medical device industry to harness additional sources of data, it is important to note that there may also be an increase in government surveillance in the marketplace.

The U.S. Food and Drug Administration (FDA) issued on July 27, 2016, a draft guidance document addressing how it may use data and evidence collected outside of the traditional clinical trial context to support medical device regulatory decision-making. The draft guidance acknowledges that certain "real-world data" (RWD) and associated "real-world evidence" (RWE) could constitute valid scientific evidence that could be used in some FDA regulatory contexts, such as support for the expansion of indications of an approved/cleared device and post-market surveillance.

While the draft guidance presents an opportunity for the medical device industry to harness additional sources of data to demonstrate safety and effectiveness and to conduct post-approval studies, it is important to note the potential for an increase in government surveillance in the marketplace. This is especially significant when considering the new unique device identification (UDI) requirements that mandate all medical devices marketed in the U.S. (with some exceptions)1 bear a unique identifier on the device or its labeling and packaging by 2020,2 allowing for more facile tracing and tracking of specific devices.3

What Kinds of RWD and RWE Does the FDA Contemplate Using?

The FDA defines RWD as data collected from sources outside of traditional clinical trials, which could include the following:

  • large simple trials
  • pragmatic clinical trials
  • prospective observational or registry studies
  • retrospective database studies
  • case reports
  • administrative and healthcare claims
  • electronic health records
  • data obtained as part of a public health investigation or routine public health surveillance
  • registries (e.g., device, procedural or disease registries)

The source of RWD may be paper or electronic inpatient and outpatient medical records and case histories, diagnostic laboratory and imaging data, patient-reported outcome measures or medical device performance data existing within a device, such as self-diagnostics, error codes and patient diagnoses/treatments delivered, including its UDI.

The FDA defines RWE as the evidence derived from the aggregation and analysis of RWD elements.

The FDA stresses that it is not changing the evidentiary standards applicable to its regulatory decision-making. Rather, the FDA believes that there are circumstances under which RWD may be used to meet existing evidentiary standards, and this draft guidance is meant to outline the criteria for determining whether particular RWD is appropriate for generating valid scientific evidence. The FDA recognizes the wealth of data collected during patient care and management, especially with the rapidly growing use of electronic data in most healthcare settings, and is working on ways to use the captured data in fulfilling its mission. The FDA has been working for several years on its plans for a national evaluation system, the goal of which is to leverage RWD to inform its decision-making.

Further, RWE may only be used when the FDA finds sufficient underlying relevance and reliability, including collection and analysis of RWD that takes into consideration the need to limit bias and is designed to assess causal relationships. In many cases, this may require a prospective analysis plan in order to ensure the proper controls are in place. The FDA states that it will consider the use of RWE to support regulatory decision-making for medical devices when it concludes that "the clinical data contained within RWD source(s) used to generate the RWE are of sufficient quality to provide confidence in the analyses necessary to inform or support the regulatory decision throughout the total product life cycle."

The draft guidance provides detail on how the FDA will assess the regulatory relevance of RWD (e.g., by assessing the representativeness of the device use in a real-world population as captured in the data source and the generalizability of the data to the relevant population being evaluated). It also provides information on how the FDA will assess the reliability of RWD, taking into consideration the methods of data accrual, the adequacy of the data to inform the question at hand, and the data quality and integrity.

How Might Valid RWE Be Used By the FDA?

The FDA lists several examples of how RWE might be used at different points in the total product life cycle to inform FDA understanding of medical device performance, including:

  • as evidence in support of expanding a device's labeling to include new indications or to update labeling with new safety and/or effectiveness information
  • for public health surveillance efforts
  • to conduct post-approval studies required as a condition of device approval

The draft guidance provides opportunities for the industry to use nontraditional forms of data to inform decisions in cases in which traditional clinical trials may be impractical or challenging, as well as cases in which data can be gathered without adding additional costs to the development of a device. However, it also provides the FDA with another means of market surveillance. Further, industry members will need to be aware of other concerns, such as patient privacy and cybersecurity, as they seek to collect and share medical device data for regulatory compliance purposes.

Comments on the draft guidance must be submitted by Oct. 25, 2016.

Before submitting comments, interested parties should seek out qualified counsel for guidance on the potential advantages and disadvantages presented by the draft guidance, including potential ancillary concerns, such as data/patient privacy and cybersecurity considerations.

Footnotes

1 The UDI rules allow for certain exceptions. For example, all Class I devices that are exempt from current Good Manufacturing Practices are also exempt from UDI requirements.

2 The rule is being phased in through 2020. Currently, most Class III devices are required to display a UDI on labeling and packaging, and most life-supporting or life-sustaining devices intended to be used more than once and reprocessed before each use are required to bear a permanent marking on the device itself. Compliance dates for other devices can be found here.

3 The FDA also issued a draft guidance on the form and content of the UDI.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions